Global Nanomedicine Therapeutics Market Research Report: Forecast (2023-2028)

Market Definition

Nanomedicine is an area of science that employs particles at the nanoscale range to be used as a treatment in case of various ailments. The major benefit of nanomaterials involves their ability to deliver drug molecules to their specific site of action & facilitate the controlled release of drugs. In this, most nanoparticles ranging from 1nm to 100nm are used, as they possess properties that are not available in bulk materials. The most significant of them include their higher reactivity & ability to pass through membranes, which play a key role in improving therapeutic activities.

Market Insights & Analysis: Global Nanomedicine Therapeutics Market (2023-28)

The Global Nanomedicine Therapeutics Market is projected to grow at a CAGR of around 12.5% during the forecast period, i.e., 2023-28. The major factors supporting the growth of the market have been their vast application in the treatment of cancer. They have shown promising results in targeted cancer therapies during the historical years. They improve the drug accumulation & pharmacokinetics of drug molecules, which has been resulting in better patient outcomes. Also, they have been found to supplement the effectiveness of other cancer therapies like radiotherapy, photothermal therapy, etc.

Further, there has been a spike in the number of cancer cases globally. Consequently, the ever-increasing number of cancer cases has been boosting the need for cancer nanomedicines over the past few years. As per International Agency for Research on Cancer (IARC), new cancer cases are expected to grow to around 27.5 million by 2040, primarily due to the rising prevalence of risk factors, such as smoking, unhealthy diet, physical inactivity, etc. Henceforth, this would further create the need for better therapeutic products for treatment in the upcoming years.

Moreover, nanomaterials contain novel physicochemical properties, which have been used to develop several neurological & cardiovascular drugs. It was attributed to their smaller size, which enhances their membrane penetration & improves intra- & intercellular interactions of the drugs. In drug development, nanomaterials have been mostly used for coating purposes, which have been found to facilitate the delivery of drugs inside the human body. The most popularly used structure was the liposomes, which have been highly commercialized as Nanoscale Drug Delivery Systems (NDDS) during 2018-2022. Moreover, considering the highly effective nature of liposomal nanoparticles as drug carriers, several companies have launched their drug candidates in the market. For instance:

• In 2020, Insmed Netherlands B.V., receive EU approval for its liposomal nanoparticle drug, i.e., Arikayce liposomal, which can be used for Respiratory Tract Infections.

In addition, in light of the enhanced adoption of liposomal nanomedicines, companies like Sierra Oncology, Inc., SynCore Biotechnology Co., Ltd., etc., have been researching their candidates, which are under clinical trial. Therefore, a long list of nanomedicines in the trial pipeline would create a great opportunity for Global Nanomedicine Therapeutics Market expansion in the forthcoming years.

Global Nanomedicine Therapeutics Market Key Driver:

Enhanced Adoption of Targeted Nanotherapies for Cancer Treatment - In cancer therapeutics, drugs are designed to affect the cell cycle mechanism, which can be controlled to inhibit the cell division of the tumor cells. Nanomedicines have been in the highest demand among all the available cancer therapeutics, owing to their nature of targeting tumor cells only. Most cancer drugs have been observed to show side effects, including the negative effect of the cell division process of non-tumoral cells. This is not the case in these therapeutics, as they have been found to effectively deliver the drug to the tumoral tissues, thus reducing other side effects caused by conventional drugs.

Henceforth, cancer being one of the major global burdens & causing the largest number of related deaths, the need for upgraded & targeted therapy was much required. Thus, companies like Johnson & Johnson, Teva Pharmaceuticals, etc., have launched & commercialized their cancer nanomedicines during the past few years. These medicines were commercialized on a large scale across Asia-Pacific, Europe, and North America, which has supported the growth of the market. Besides, companies like Celgene, Halozyme Therapeutics, etc., have also been investing in the R&D of targeted Nano therapies for cancer. Thus, these target nano therapies under clinical trials have the potential to create lucrative opportunities for the growth of the Global Nanomedicine Therapeutics Market during 2023-28.

Global Nanomedicine Therapeutics Market Possible Restraint:

Arising Incidence of Nanotoxicity to Hamper the Market Growth - The growing incidences of nanotoxicity have been found during the past few years, which have been majorly caused by the usage of metal nanoparticles in nanomedicines. This is primarily due to reduced biocompatibility coupled with lower biodegradation & accumulation in organs like the liver, spleen, etc. These side effects have been observed to hamper the adoption of nanoparticle-based nanomedicines among patients, which has impeded Global Nanomedicine Therapeutics Market expansion.

Moreover, the detection of the toxic effects of several nanomedicines has also terminated their clinical trial during the time of development. Subsequently, the incidence of nano toxicities, combined with the termination of clinical trials, has been negatively affecting the market growth over the past few years. Furthermore, there has been the unavailability of a proper detection method, coupled with the lack of development funds, affecting the proper safety evaluation of these therapeutics. Thus, nanotoxicity would also act as a barrier to the Global Nanomedicine Therapeutics Market in the following years.

Global Nanomedicine Therapeutics Market Growth Opportunity:

Incorporating AI & Big Data into Cancer Therapeutics - In recent years, the integration of artificial intelligence (AI) & big data analytics across nanomedicine development laboratories has gained significant traction. AI & big data have been largely used for the rational design of NPs, laboratory medicine, and clinical imaging based on recently established techniques. Also, some researchers have been using artificial neural networks [ANN] to enable the rational design of electromagnetic plasmonic nanostructures. These structures would be used to determine the physical characteristics & functionalities of nanoparticles (NPs). For instance:

• In 2023, according to the Institute of Functional Materials & Biofabrication, Germany, artificial intelligence would be used for single blood vessel analysis, further leveraging in designing protein nanoparticle-based drug delivery systems.

Going forward, it is presumed that the adoption of AI & big data analytics by pharmaceutical companies for the development of these therapeutics would support the growth of the market in the forecasted years.  

Global Nanomedicine Therapeutics Market Key Trend:

Development of Nucleic Acid-based Nanocarriers for Targeted Drug Delivery - Nanocarriers based on nucleic acids have emerged as powerful & novel nanocarriers that can meet the demand for tissue-specific targeting in recent years. They have been found to show good biocompatibility, low toxicity, and programmable structures, and their advantages include controllable size & modifiability. Henceforth, this has amplified the R&D activities of companies to develop novel hybrids, including DNA, RNA, and DNA/RNA hybrid nanocarriers. These nucleic-acid carriers have found application across different diseases, like cancer, infection, pain relief, etc., in recent years, thus, escalating the adoption of nanocarrier-based nanomedicines across healthcare facilities.

Also, the companies like Pfizer, Moderna, etc., are actively focussing on developing drugs based on Nanocarriers using nucleic acid to identify their role in other unexplored therapies like pain relief, infection, etc. Hence, with the improved R&D initiatives for the development of nucleic-acid-based carriers, their application areas would amplify, which would further help the market to expand its revenue in the upcoming years as well.

Global Nanomedicine Therapeutics Market (2023-28): Segmentation Analysis

The Global Nanomedicine Therapeutics Market study of MarkNtel Advisors evaluates & highlights the major trends & influencing factors in each segment & includes predictions for the period 2023–2028 at the global, regional, and national levels. Based on the Application, and Indication the market has been further classified as:

Based on Application:

• Drug Delivery
• Regenerative Medicine
• Vaccines
• Active Implants  
• Others (Controlled Drug Release, Combination therapy, etc.)

Drug Delivery has acquired a significant share in the Global Nanomedicine Therapeutics Market during the historical years. It was majorly attributed to the target identification & controlled delivery features of nanoparticle-coated drugs. Primary nanoparticles, which have been highly commercialized in drug delivery since the historical years include liposomes, gold nanoparticles, etc. Several liposome-coated drugs designed for targeted delivery, such as Cytarabine/daunorubicin, Arikayce, etc., have been marketed by Insmed & Alnylam, respectively, during the past few years & contributed to the growth of the segment.

Besides, after the approval of vaccines for COVID-19, designed using nanomedicine, the segment has become a hot topic for research. Companies like Pfizer, Moderna, BioNtech, etc., further invested in the R&D of nanomedicine-based vaccines, which are anticipated to receive approvals during the forecast period. Hence, as more vaccines, based on nanoparticles would get approved, the segment is presumed to dominate the Global Nanomedicine Therapeutics Market in the future years.

Based on Indication:

• Oncology
• Infectious Disease
• Cardiology
• Neurological Disease
• Others (Orthopaedics, Urology, etc.)

Of them all, Oncology has been one of the most widely accessed indications of nanomedicines. It is mainly because nanotechnology has a vast application in cancer treatment, imaging, etc. These therapeutics created a breakthrough in the targeted therapies for cancer treatment, as most of the drug agents designed for treatment were found to deliver numerous side effects. They are designed to be delivered at targeted cancer locations only, which reduces many side effects caused by cancer treatments. Also, with the growing awareness of the promising results achieved by the usage of nanoparticles for cancer treatment, their demand has escalated significantly in historical years.

Further, companies like ImmunoVaccine Technologies, Inc., MedImmune LLC, etc., have been actively investing in the R&D of new nanomedicine-based cancer therapies. These efforts by the companies are in line to cater to the upcoming demand for them in oncology, majorly due to growing awareness. Hence, the segment is anticipated to witness upscaled growth in the ensuing years, further supporting in upscaling the revenue growth of the Global Nanomedicine Therapeutics Market.

Global Nanomedicine Therapeutics Market Regional Projection

Geographically, the Global Nanomedicine Therapeutics Market expands across:

• North America
• South America
• Europe
• The Middle East & Africa
• Asia-Pacific

North America held a significant portion of the Global Nanomedicine Therapeutics Market & is anticipated to continue to hold this position during the forecast period as well. The major factors responsible for themarket growth included the rise in the number of deadly infectious diseases across the region, which has upscaled the demand graph of nanomedicines. In addition to this, the presence of world-class R&D infrastructure and an increase in government spending in the healthcare system has supported the market across the region.

Moreover, there has been a presence of significant key players across the nation, like Pacira BioSciences, Moderna, etc., who have been actively involved in the development of novel therapies against emerging diseases. Henceforth, the availability of newly emerged nanomedicines for the treatment of diseases across different indications would help the region to dominate the market in the forecasted years as well.

Global Nanomedicine Therapeutic Industry Recent Developments 

• 2022: Clene Nanomedicine announced the phase 2 trial result of its CNM-Au8 drug, which is designed for the treatment of neurodegenerative diseases. The study showed positive results by significantly reducing the disease progression of Amyotrophic Lateral Sclerosis.
• 2022: Glaxo Smith Kline Plc., has announced that it received prequalification approval from the World Health Organization (WHO) for Mosquirix, which is a liposome-based vaccine for malaria. This vaccine has been allowed to use across countries with a higher prevalence of malaria caused by P. falciparum.

Gain a Competitive Edge with Our Global Nanomedicine Therapeutics Market Report

1. Global Nanomedicine Therapeutics Market report provides a detailed and thorough analysis of market size, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics and make informed decisions.
2. This report also highlights current market trends and future projections, allowing businesses to identify emerging opportunities and potential challenges. By understanding market forecasts, companies can align their strategies and stay ahead of the competition.
3. Global Nanomedicine Therapeutics Market report aids in assessing and mitigating risks associated with entering or operating in the market.
4. The report would help in understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks and optimize their operations.